Systemic treatment of hepatocellular carcinoma in a patient with hemophilia A: A case report
| Autor: | Jelena Radic, Ivana Kolarov-Bjelobrk, Tijana Vasiljevic, Bojana Vranjkovic, Vladimir Vidovic, Nemanja Petrovic |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Medical review. 74:388-390 |
| ISSN: | 1820-7383 0025-8105 |
| DOI: | 10.2298/mpns2112388r |
| Popis: | Introduction. Hepatocellular carcinoma is a serious problem for patients with hemophilia. Hepatitis C virus infection is the most common comorbidity in adult patients with inherited bleeding disorders, including hemophilia. Case Report. This is a case report of a 65-year-old male patient with hemophilia A and hepatocellular carcinoma. Sorafenib treatment was initiated at a dose of 400 mg/day, after a 50% dose reduction. In order to prevent bleeding episodes, prophylactic doses of replacement plasma-derived factor VIII concentrate (40 U/kg of body weight three times a week) were introduced. Our patient received a total of ten cycles of sorafenib therapy, in good general condition, without bleeding episodes. Conclusion. Differential chemotherapy is not contraindicated in patients with inherited bleeding disorders, provided that adequate hemostasis is achieved. In such cases, a multidisciplinary approach is necessary for the management of hemophilia during systemic cancer treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|